Business Context and Reporting Period
This Form 8-K Current Report from Minerva Neurosciences, Inc. covers events occurring on June 17, 2015. The filing details the adoption of a new Non-Employee Director Compensation Plan effective July 1, 2015, and reports the results of the 2015 Annual Meeting of Stockholders held in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and compensation arrangements rather than financial performance metrics.
Material Changes and Governance Actions
Director Compensation Plan
- Effective Date: July 1, 2015.
- Cash Retainers: Non-employee directors receive $30,000 annually. The Chairman receives an additional $50,000.
- Committee Fees: Audit Committee chairs receive $15,000; Compensation Committee chairs receive $10,000; Nominating and Corporate Governance Committee chairs receive $7,000. Other members receive $7,500, $5,000, and $3,500 respectively.
- Equity Grants: New directors receive a one-time option for 25,000 shares (vesting quarterly over three years). Annual grants consist of options for 12,500 shares (vesting quarterly over one year).
Stockholder Vote Results
- Proposal 1 (Election of Directors): Michèle Ollier, MD and Nico Vandervelpen were elected. Both received over 14 million votes "For" with approximately 20,000 votes "Withheld" and 1,997,300 "Broker Non-Votes."
- Proposal 2 (Ratification of Auditors): Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ended December 31, 2015. Votes were 16,074,112 "For," 8,973 "Against," and 7,161 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the adoption of the compensation plan and the outcome of the annual meeting.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the Director Welcome Options (25,000 shares) and Annual Grants (12,500 shares).
- Review the full text of the Non-Employee Director Compensation Plan (Exhibit 10.1) for complete terms and conditions.
- Confirm the total number of shares eligible for voting at the Annual Meeting to contextualize the "Broker Non-Votes" count.